Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
FAIL · Does not pass the screen
61.23 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 06:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price61.23 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.50)
Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 61.23 against the desk's fair-value range, base estimate 106.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.50, read 2026-10-28
Ethical does not pass the values gate
Price61.23 USD
Fair value106.00
Ethical score70.0/100
Our investment reviews on this name
2026-08-26Read Markdown77.46-21.0% to today ✓Markup gives way to Markdown after a 10% rise in 8 weeks
2026-07-02Read Markup70.15-12.7% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Cytokinetics, Incorporated holds its Markdown at $61.23. The statistical read favours the sellers, held for 65 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 65 days
Price at the screen
$61.23
Valuation
N/A trailing · -14.06 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.41
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
90.15%
Below 33%
Interest-bearing debt is 90.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
23.52%
Below 33%
Cash held in interest-bearing accounts and securities is 23.5% of assets, under the one-third limit.
Pass
Receivables
9.85%
Below 49%
Money owed to the company is 9.8% of assets, under the 49% limit.
Pass
Revenue purity
55.00%
Below 5%
55.0% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Cytokinetics,'s business is in a permissible area, but its interest-bearing debt is about 90% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CYTK's ethical verdict changes
Today CYTK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 73.1% margin of safety to the base estimate.
Third-party analyst targets: 20 covering, consensus Strong Buy. The average target sits +73% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Muscle drug bets without profits in sight
Picture a lab racing to fix failing muscles in rare diseases, yet still waiting for its first real payday. Cytokinetics has posted eye-watering revenue growth after launching its first product, and twenty analysts see further upside to the same fair value we calculate. The ethical screen clears it, but that is where the case stops.
We pass. A forward multiple that sits in negative territory and a profit margin of zero tell the real story: this remains a cash-burning research outfit whose next steps hinge on clinical data rather than steady demand. Unknown competitive protection adds another layer of uncertainty that standard numbers cannot resolve.
High binary risk sits around every biotech launch, from trial failures to fresh share issues that dilute holders. The growth spurt looks impressive on paper, yet it sits atop a business that has yet to prove it can keep money once the early sales fade. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CYTK trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markdown$62.65+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 93%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (20 analysts) rates it buy, with a mean price target of $105. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$62.65-0.4%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 93%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (20 analysts) rates it buy, with a mean price target of $105. Insiders have been net sellers over the past quarter.
2026-10-14Markdown$62.91-4.1%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 93%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (20 analysts) rates it buy, with a mean price target of $105. Insiders have been net sellers over the past quarter.
2026-10-02Markdown$65.62-15.3%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 93%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (20 analysts) rates it buy, with a mean price target of $105. Insiders have been net sellers over the past quarter.
2026-08-26Markdown · changed$77.46-3.4%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 93%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (20 analysts) rates it buy, with a mean price target of $105.
2026-07-26Markup$80.18+14.3%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 93%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (20 analysts) rates it buy, with a mean price target of $105.
2026-07-18Markup$70.15+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 93%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (20 analysts) rates it buy, with a mean price target of $105.
2026-07-03Markup$70.15+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$70.15Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
